Drug intelligence / Profile preview

CMD003

Development stage: Preclinical
Lead developer: Kuur Therapeutics
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

CMD003 is a preclinical protein-based therapeutic candidate being developed by COMED Therapeutics for the treatment of malaria. The drug is designed to be delivered using COMED's proprietary intracellular delivery platform, which facilitates the transport of macromolecules like proteins, peptides, and nucleic acids into cells. While the specific molecular target and mechanism of action have not been publicly disclosed, the program aims to leverage this delivery technology to address malaria infection at the cellular level.

Other names: baltaleucel-T

Targets

EBNA1 (Epstein-Barr virus latency proteins)

Beyond the preview

Go deeper on CMD003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMD003.

Explore the full profile